🚀 VC round data is live in beta, check it out!
Procter & Gamble Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for Procter & Gamble Health and similar public comparables like Sido Muncul, Genomma Lab, Safilo Group, Synsam and more.
Procter & Gamble Health Overview
About Procter & Gamble Health
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
Founded
1967
HQ
Employees
1.3K
Website
Financials (LTM)
EV
$909M
Procter & Gamble Health Financials
Procter & Gamble Health reported last 12-month revenue of $147M and EBITDA of $46M.
In the same LTM period, Procter & Gamble Health generated $106M in gross profit, $46M in EBITDA, and $34M in net income.
Revenue (LTM)
Procter & Gamble Health P&L
In the most recent fiscal year, Procter & Gamble Health reported revenue of $137M and EBITDA of $36M.
Procter & Gamble Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $147M | XXX | $137M | XXX | XXX | XXX |
| Gross Profit | $106M | XXX | $69M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $46M | XXX | $36M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $34M | XXX | $27M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Procter & Gamble Health Stock Performance
Procter & Gamble Health has current market cap of $941M, and enterprise value of $909M.
Market Cap Evolution
Procter & Gamble Health's stock price is $56.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $909M | $941M | 0.4% | XXX | XXX | XXX | $1.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProcter & Gamble Health Valuation Multiples
Procter & Gamble Health trades at 6.2x EV/Revenue multiple, and 19.9x EV/EBITDA.
EV / Revenue (LTM)
Procter & Gamble Health Financial Valuation Multiples
As of March 7, 2026, Procter & Gamble Health has market cap of $941M and EV of $909M.
Equity research analysts estimate Procter & Gamble Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Procter & Gamble Health has a P/E ratio of 27.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $941M | XXX | $941M | XXX | XXX | XXX |
| EV (current) | $909M | XXX | $909M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 19.9x | XXX | 24.9x | XXX | XXX | XXX |
| EV/EBIT | 20.2x | XXX | 25.9x | XXX | XXX | XXX |
| EV/Gross Profit | 8.6x | XXX | 13.1x | XXX | XXX | XXX |
| P/E | 27.9x | XXX | 35.4x | XXX | XXX | XXX |
| EV/FCF | 24.4x | XXX | 43.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Procter & Gamble Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Procter & Gamble Health Margins & Growth Rates
Procter & Gamble Health's revenue in the last 12 month grew by 11%.
Procter & Gamble Health's revenue per employee in the last FY averaged $0.1M.
Procter & Gamble Health's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Procter & Gamble Health's rule of X is 58% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Procter & Gamble Health Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Procter & Gamble Health Public Comps
See public comps and valuation multiples for other Health & Beauty and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sido Muncul | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomma Lab | XXX | XXX | XXX | XXX | XXX | XXX |
| Safilo Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Synsam | XXX | XXX | XXX | XXX | XXX | XXX |
| Edgewell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Procter & Gamble Health M&A Activity
Procter & Gamble Health acquired XXX companies to date.
Last acquisition by Procter & Gamble Health was on XXXXXXXX, XXXXX. Procter & Gamble Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Procter & Gamble Health
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProcter & Gamble Health Investment Activity
Procter & Gamble Health invested in XXX companies to date.
Procter & Gamble Health made its latest investment on XXXXXXXX, XXXXX. Procter & Gamble Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Procter & Gamble Health
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Procter & Gamble Health
| When was Procter & Gamble Health founded? | Procter & Gamble Health was founded in 1967. |
| Where is Procter & Gamble Health headquartered? | Procter & Gamble Health is headquartered in India. |
| How many employees does Procter & Gamble Health have? | As of today, Procter & Gamble Health has over 1K employees. |
| Is Procter & Gamble Health publicly listed? | Yes, Procter & Gamble Health is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Procter & Gamble Health? | Procter & Gamble Health trades under PGHL ticker. |
| When did Procter & Gamble Health go public? | Procter & Gamble Health went public in 1996. |
| Who are competitors of Procter & Gamble Health? | Procter & Gamble Health main competitors are Sido Muncul, Genomma Lab, Safilo Group, Synsam. |
| What is the current market cap of Procter & Gamble Health? | Procter & Gamble Health's current market cap is $941M. |
| What is the current revenue of Procter & Gamble Health? | Procter & Gamble Health's last 12 months revenue is $147M. |
| What is the current revenue growth of Procter & Gamble Health? | Procter & Gamble Health revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Procter & Gamble Health? | Current revenue multiple of Procter & Gamble Health is 6.2x. |
| Is Procter & Gamble Health profitable? | Yes, Procter & Gamble Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Procter & Gamble Health? | Procter & Gamble Health's last 12 months EBITDA is $46M. |
| What is Procter & Gamble Health's EBITDA margin? | Procter & Gamble Health's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Procter & Gamble Health? | Current EBITDA multiple of Procter & Gamble Health is 19.9x. |
| What is the current FCF of Procter & Gamble Health? | Procter & Gamble Health's last 12 months FCF is $37M. |
| What is Procter & Gamble Health's FCF margin? | Procter & Gamble Health's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Procter & Gamble Health? | Current FCF multiple of Procter & Gamble Health is 24.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.